Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Déambulation assistée pour améliorer les résultats de santé des patients hospitalisés plus âgés

4 novembre 2026 mis à jour par: Michael Rothberg, The Cleveland Clinic

Essai randomisé d'ambulation assistée pour améliorer les résultats de santé des patients hospitalisés plus âgés

The investigator proposes to conduct a randomized trial of supervised ambulation delivered by mobility technician (MT) up to three times daily, including weekends, to hospitalized medical patients. The aims of the study are to compare the short and intermediate-term outcomes of patients randomized to the intervention versus those patients randomized to receive usual care, to identify patients who are most likely to benefit from the intervention and to assess whether the intervention increases or decreases overall costs of an episode of care, including the cost of the MTs, the index hospitalization and the first 30 days post enrollment.

Aperçu de l'étude

Description détaillée

The investigator proposes to conduct a large randomized trial to test the impact of MTs (Mobility Technicians) on short and intermediate term outcomes for 3000 patients aged 65 years and older at 5 hospitals in 2 health systems. Patients will be randomized to receive supervised ambulation up to 3 times daily with a MT or to receive usual care. All participants will wear an accelerometer on their wrist to track their movement throughout the hospital stay. The study has 3 aims. First, the study will compare the mobility of patients at discharge (or 10 days) to assess the impact of the MTs on this outcome. Of particular interest is whether the use of MTs will increase the proportion of patients who can go home vs.post-acute care, and whether the improvements in mobility are sustained at 30 days. Second, the study will use predictive modeling to identify which patients are most likely to benefit from this intervention. Third, the study will assess the impact of the intervention on overall costs associated with the episode of care, including inpatient costs and the 30 days post enrollment. This information will be important to convince health systems to adopt this approach.

Type d'étude

Interventionnel

Inscription (Estimé)

3000

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Michael Rothberg, M.D.
  • Numéro de téléphone: 216-445-0719
  • E-mail: rothbem@ccf.org

Lieux d'étude

    • Massachusetts
      • Springfield, Massachusetts, États-Unis, 01199
    • Ohio
      • Cleveland, Ohio, États-Unis, 44111
        • Recrutement
        • Fairview Hospital
        • Contact:
          • Michael Rothberg, MD
          • Numéro de téléphone: 216-445-0719
          • E-mail: rothbem@ccf.org
      • Cleveland, Ohio, États-Unis, 44195
        • Recrutement
        • Cleveland Clinic- Main Campus
        • Contact:
          • Michael Rothberg, MD
          • Numéro de téléphone: 216-445-0719
          • E-mail: rothbem@ccf.org
      • Garfield Heights, Ohio, États-Unis, 44125
        • Résilié
        • Marymount Hospital
      • Mayfield Heights, Ohio, États-Unis, 44124
        • Recrutement
        • Hillcrest Hospital
        • Contact:
          • Aaron Hamilton, MD
          • Numéro de téléphone: 440 312-3000
          • E-mail: HAMILTA3@ccf.org

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

65 ans et plus (Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

Participants must meet all of the inclusion criteria listed below to participate in this study:

  1. ≥65 years of age
  2. Admitted to a medical service
  3. Complete history and physical examination on file
  4. 6-Clicks score of 16-23
  5. Insurance with Traditional Medicare or Medicare Advantage

Exclusion Criteria:

Any patient meeting any of the exclusion criteria listed below at baseline will be excluded from study participation:

  1. Significant language barrier that requires a translator (other than Spanish at Baystate site only)
  2. Discharge planned for that day or the following day
  3. Observation status
  4. Surgical procedure planned
  5. Patients diagnosed with unstable angina or other medical conditions precluding participation in exercise/ambulation
  6. Permanent residence in a skilled nursing facility
  7. Comfort care measures only
  8. >48 hours since admission
  9. Active infection with COVID-19
  10. Other active infection requiring contact or droplet precautions
  11. Order for bedrest

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Usual Care

No intervention

Expérimental: Mobility Technician

Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session

Designated mobility technicians (MT) will ambulate hospitalized medical patients up to 3 times daily, 7 days per week, until discharge or a maximum of 10 days. Each day, the MT will visit the patient 4 times or until the patient successfully ambulates 3 times that day. In cases where a PT has provided a recommendation in the patient's chart, the MT will follow the recommendation, if feasible. Otherwise, the MT will execute the standard mobility protocol. The mobility protocol will allow the MT to assist a patient with an appropriate out-of-bed activity based on their 6-clicks score from the immediately preceding session.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in Short Physical Performance Battery (SPPB) from admission
Délai: Up to 10 days

Every patient will have an SPPB score on admission to the study. A blinded assessor will measure the SPPB again at discharge or on day 10 if the patient is still hospitalized. The primary outcome is change from admission to discharge. Investigators will also compare the percentage of patients who reach the minimal clinically important difference of 1 point.

SPPB minimum value= 0 SPPB maximum value= 12 (higher score indicates a better outcome). If no blinded team member is available, the evaluation may be carried out by any unblinded team member. The blinding status of the evaluator will be noted in REDCap.

Up to 10 days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Patient-Reported Outcomes Measurement Information System (PROMIS) physical function - mobility
Délai: 30 days post enrollment

Patients will complete the PROMIS physical function mobility bank via REDCap at 30 days post enrollment. PROMIS allows use of computer-adapted testing to measure patient-reported outcomes. The mobility question bank focuses on activities of physical mobility such as getting out of bed or a chair to walking up stairs. PROMIS measures were developed and validated with state-of-the-science methods supported by National Institutes of Health (NIH) funding. PROMIS was designed to enhance communication between clinicians and patients in diverse research and clinical settings and to be relevant across all conditions for the assessment of symptoms and functions.

PROMIS minimum value= 0 PROMISE maximum value= 100 (higher score indicates a better outcome)

30 days post enrollment
Activity Measure for Post-Acute Care (AM-PAC) basic mobility outpatient short form (SF)
Délai: 30 days post enrollment

Subjects will complete the AM-PAC at 30 days post enrollment and the score will be transformed using the t-scale. In addition to comparing AM-PAC scores at 30 days, the investigator will also compare change in t-score from admission. The AM-PAC 6-clicks (assessed in the hospital) and the AM-PAC outpatient SF are normed to the same t-scale, allowing for conversion from the one to the other. The 6-clicks is scored by a clinical proxy, while the SF AM-PAC is self-reported, allowing for initial assessment by the MT and 30-day self-report by the patient. Previous studies have demonstrated adequate validity of mobility assessment via the AM-PAC using clinical or family proxies. To improve interpretability, investigators will compare the percentage of patients who reach the minimal clinically important difference of 3 points on the t-scale.

AM-PAC minimum value= 29.41 AM-PAC maximum value= 80.30 (higher score indicates a better outcome)

30 days post enrollment
Hospital-Acquired Complications
Délai: 10 days

Composite outcome of venous thromboembolism, fall with injury, pressure ulcers or hospital-acquired pneumonia. Hospital-acquired complications will be identified from the electronic health record and from the falls reporting system. All falls will be examined, whether occurring during assisted ambulation or otherwise. Only falls with injury will be included in the hospital-acquired complications measure. Outcomes will be adjudicated by blinded reviewers. While investigators are primarily interested in the composite measure, investigators will also examine the individual components separately.

10 days
Number of Patients with Readmission within 30 days
Délai: 30 days after discharge

All cause readmission within 30 days of discharge from the index hospitalization.

30 days after discharge
Activities of Daily Living
Délai: 30 days post enrollment

Activities of daily living as measured by the Katz and Lawton scales.

Katz minimum value= 0 Katz maximum value= 6 (higher score indicates a better outcome) Lawton minimum value= 0 Lawton maximum value= 8 (higher score indicates a better outcome)

30 days post enrollment
Frailty
Délai: 30 days post enrollment

Frailty as measured by the Fatigue, Resistance, Ambulation,Illness, and Loss of weight (FRAIL) scale.

FRAIL minimum value= 0 FRAIL maximum value= 5 (higher score indicates a worse outcome)

30 days post enrollment
Total episode cost
Délai: Admission to 30 days post enrollment

Investigators will estimate total cost of the episode of care including the index admission (from hospital cost accounting systems), the personnel costs for the MTs (using hourly wages plus benefits), and all non-medication costs for the 30 days post-enrollment (from Medicare claims).

Admission to 30 days post enrollment
Number of Patients Discharged to Home
Délai: date of randomization to date of discharge, up to 30 days

Based on the discharge disposition in the medical record, investigators will identify whether the patient was discharged to home.

date of randomization to date of discharge, up to 30 days
Length of Stay
Délai: date of admission to date of discharge, up to 30 days

Length of stay will be calculated as whole days from the time of admission to the time of discharge.

date of admission to date of discharge, up to 30 days
Mortality
Délai: 30 days from admission

Patient's vital status will be ascertained from the EHR, Medicare claims or from follow-up phone calls.

30 days from admission
Total episode cost
Délai: Admission to 6 months after enrollment

Investigators will estimate total cost of the episode of care including the index admission (from hospital cost accounting systems), the personnel costs for the MTs (using hourly wages plus benefits), and all non-medication costs for the 6 months post-enrollment (from Medicare claims).

Admission to 6 months after enrollment
Falls post-discharge
Délai: 30 days from admission

Whether the patient has fallen, whether it was multiple times and whether an injury occurred will be assessed via telephone

30 days from admission
RCSQ (Richards Campbell Sleep Questionnaire)
Délai: Days 1-10

Five question sleep survey which measures overall quality of sleep. Patients in both study arms will complete the questionnaire each morning regarding the previous night's sleep.

Days 1-10

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Michael Rothberg, M.D., The Cleveland Clinic

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

15 mai 2023

Achèvement primaire (Estimé)

30 novembre 2026

Achèvement de l'étude (Estimé)

30 décembre 2026

Dates d'inscription aux études

Première soumission

11 janvier 2023

Première soumission répondant aux critères de contrôle qualité

10 février 2023

Première publication (Réel)

13 février 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner